Wouters J, Ooms F
Facultés Universitaires Notre-Dame de la Paix, Chimie Moleculaire Structurale, Namur, Belgium.
Curr Pharm Des. 2001 May;7(7):529-45. doi: 10.2174/1381612013397889.
Crystal structures of small molecules (i.e. isolated ligands) are a source of valuable structural information helpful in the process of drug design (pharmacophore model elaborations, 3D QSAR, docking, and de novo design). Indeed, structural data obtained from small molecules crystallography can approach ligand-receptor binding by providing unique structural features both about the conformation (internal geometry) of the ligand (s) and about the intermolecular interaction potentially occurring within the active site of a target (enzyme/receptor). Small molecule crystal structure databases can also be used in three dimensional search to identify new drug candidates. Future development in small molecule crystallography (e.g. powder diffraction) should also provide original solutions to complex problems related to polymorphism.
小分子(即孤立配体)的晶体结构是有价值的结构信息来源,有助于药物设计过程(药效团模型构建、三维定量构效关系、对接和从头设计)。实际上,从小分子晶体学获得的结构数据可以通过提供有关配体构象(内部几何结构)以及靶标(酶/受体)活性位点内可能发生的分子间相互作用的独特结构特征,来接近配体-受体结合。小分子晶体结构数据库也可用于三维搜索以识别新的候选药物。小分子晶体学的未来发展(例如粉末衍射)也应为与多晶型相关的复杂问题提供原始解决方案。